[{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP||SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP||SGLT2","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP","graph1":"Undisclosed","graph2":"Phase I","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP","graph1":"Undisclosed","graph2":"Phase I","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Icosabutate","moa":"CETP","graph1":"Undisclosed","graph2":"Phase I","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Olive","moa":"Immune","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Endocrinology","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2013","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"10","companyTruncated":"BASF \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"BASF","sponsor":"Nutrasource","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2016","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Nutrasource","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ Nutrasource"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"Prostaglandin G\/H synthase 2; Prostaglandin G\/H synthase 1; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta; Free fatty acid receptor 1; Sodium\/calcium exchanger 1; Fatty acid-binding protein, brain; Acyl-CoA (8-3)-desaturase; Long-chain-fatty-acid--CoA ligase 4; Transient receptor potential cation channel subfamily V member 1; Peroxisome proliferator-activated receptor alpha; Polyunsaturated fatty acid 5-lipoxygenase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Icosapent Ethyl","moa":"Prostaglandin G\/H synthase 2; Prostaglandin G\/H synthase 1; Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor delta; Free fatty acid receptor 1; Sodium\/calcium exchanger 1; Fatty acid-binding protein, brain; Acyl-CoA (8-3)-desaturase; Long-chain-fatty-acid--CoA ligase 4; Transient receptor potential cation channel subfamily V member 1; Peroxisome proliferator-activated receptor alpha; Polyunsaturated fatty acid 5-lipoxygenase","graph1":"Sleep","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDONESIA","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"CLA-Fortified Milk","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"GERMANY","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Hepaxa","moa":"Undisclosed","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Omega-3 Concentrate","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDONESIA","productType":"Plant Extract\/Herbal","year":"2024","type":"Inapplicable","leadProduct":"Palm Oil Enriched With Plant Sterols","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"BASF \/ BASF","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ BASF"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Pronova Pure","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NORWAY","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Pronova Pure Triglycerides","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BASF \/ Undisclosed"},{"orgOrder":0,"company":"BASF","sponsor":"BASF","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Pronovapure","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ PRONOVA BIOPHARMA NORGE AS","highestDevelopmentStatusID":"1","companyTruncated":"BASF \/ PRONOVA BIOPHARMA NORGE AS"},{"orgOrder":0,"company":"BASF","sponsor":"Joe Chan","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"NORWAY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"steroids (androgens","graph1":"Immunology","graph2":"Phase III","graph3":"BASF","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BASF \/ Joe Chan","highestDevelopmentStatusID":"10","companyTruncated":"BASF \/ Joe Chan"}]

Find Clinical Drug Pipeline Developments & Deals by BASF

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Palm Oil Enriched With Plant Sterols is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of Hyperlipidemias.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Palm Oil Enriched With Plant Sterols

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Undisclosed

                          Recipient : Institut Pertanian Bogor

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : CLA-Fortified Milk is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Obesity.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          August 28, 2020

                          Lead Product(s) : CLA-Fortified Milk

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Undisclosed

                          Recipient : Indonesia University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Hepaxa is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          January 11, 2019

                          Lead Product(s) : Hepaxa

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Olive Oil is a Plant Extract/Herbal drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Inapplicable

                          July 19, 2018

                          Lead Product(s) : Olive

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : Northumbria University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : EPA is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Sleep.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 18, 2018

                          Lead Product(s) : Icosapent Ethyl

                          Therapeutic Area : Sleep

                          Highest Development Status : Undisclosed

                          Recipient : Northumbria University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : EPA is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 18, 2017

                          Lead Product(s) : Icosapent Ethyl

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : Northumbria University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Linoleic Acid is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          April 14, 2017

                          Lead Product(s) : Linoleic Acid

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Undisclosed

                          Recipient : Washington University School of Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Omega-3 Acid Ethyl Esters is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Transplantation.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 11, 2017

                          Lead Product(s) : Omega-3-Acid Ethyl Esters 90

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Joe Chan

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Omega-3 is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

                          Product Name : Undisclosed

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          October 05, 2016

                          Lead Product(s) : Omega-3

                          Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                          Highest Development Status : Undisclosed

                          Sponsor : Nutrasource

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          AllPack Indonesia
                          Not Confirmed
                          AllPack Indonesia
                          Not Confirmed

                          Details : Pronovapure is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Cognition.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          May 05, 2016

                          Lead Product(s) : Pronovapure

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Recipient : Northumbria University

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank